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Key Points
•Obesity is not associ-
ated with MGUS or
LC-MGUS.
•High body mass index
during midlife is asso-
ciated with increased
risk of progressing from
MGUS and LC-MGUS
to MM and other LP
diseases.
All multiple myeloma (MM) cases are preceded by the premalignant state monoclonal
gammopathy of undetermined signiﬁcance (MGUS). Results from previous studies show a
positive association between obesity andMM; however, the association between obesity and
MGUS is controversial. The aims were to determine (1) if obesity is associated with an
increased risk of MGUS and light-chain MGUS (LC-MGUS) and (2) whether obesity is
associated with a higher risk of progression to MM and other lymphoproliferative (LP)
diseases. Data from the population-based Age, Gene/Environment Susceptibility–Reykjavik
Study (N 5 5764) were used. We performed serum protein electrophoresis and serum free
light-chain assay on all subjects to identify MGUS and LC-MGUS cases. We included 11
different measures on current and previous obesity in our analysis. Logistic regression and
Cox proportional-hazard regression were used to analyze the associations. A total of
300 (5.2%) MGUS and 275 (4.8%) LC-MGUS cases were identiﬁed. During a median follow-up
of 8 years, 18 had progressed to MM and 11 to other LP diseases. We found no association
between the 11 obesity markers and MGUS or LC-MGUS (odds ratios 0.81 to 1.15 for all 11
variables in both conditions). Interestingly, we found that high midlife body mass index
increased risk of progression toMMand other LP diseases (hazard ratio, 2.66; 95% conﬁdence
interval, 1.17-6.05). To conclude, obesity was not associated with MGUS. However, we found
overweight/obesity to be a risk factor for progression from MGUS to MM and other LP
diseases, suggesting that obesity plays a role in the transformation of MGUS to MM.
Introduction
Overweight and obesity have consistently been recognized as risk factors for many common
cancers.1-4 The World Health Organization (WHO) recently concluded that there is now
sufficient evidence for the effect of weight on 13 types of cancers, including multiple myeloma
(MM).5,6 MM is a chronic B-cell disorder characterized by a monoclonal proliferation of plasma
cells in the bone marrow.7 All cases of MM are preceded by the premalignant state monoclonal
gammopathy of undetermined significance (MGUS),8,9 which is an asymptomatic condition
characterized by the presence of an M-protein in serum without evidence of MM or other
lymphoproliferative (LP) diseases.10 The prevalence of MGUS increases with age and is reported
to be found in ;5% of individuals older than 70 years.11 The average risk of progression from
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MGUS to MM is estimated to be 1% per year.12,13 Light-chain MGUS
(LC-MGUS) has recently been described as a precursor condition to
light-chain MM.14,15 LC-MGUS is defined as an abnormal free light-
chain (FLC) ratio with no expression of heavy chains, along with an
increased concentration of the light chain involved, and its prevalence
has been estimated to be 0.7% to 0.8%.14,15
The etiology of MGUS and LC-MGUS is to a large extent unknown.
However, researchers have found higher risk of MGUS among
males,11 blacks,16,17 those with family history of MGUS and related
diseases,18 and those with prior personal and family history of
immune-related conditions.19,20 Obesity has been identified as a risk
factor for MM, with6,21,22 2 meta-analyses finding a 10% to 20%
increased risk of MM for a 5 kg/m2 increase in body mass index
(BMI).21,22 However, BMI is a limited measurement as it does not
provide information on fat distribution, which is of importance as many
of the complications associated with obesity have been shown to be
closely related to abdominal obesity.23,24 A recent pooled analysis of
20 prospective studies found that waist circumference is a risk factor
for MM mortality and that BMI in early adulthood plays an important
role later in life regarding MM mortality, particularly in women.25 In
addition, a recent cross-sectional study (n 5 72) found that patients
recently diagnosed with MM had higher abdominal fat compared with
patients with MGUS, indicating that this parameter might serve as a
biomarker for progression from MGUS to MM.26
The biological mechanisms through which obesity might influence
MM etiology are not yet established. Suggested mechanisms are
effects of interleukin-6 (IL-6), insulin-like growth factor 1, and
adiponectin. IL-6 is directly associated with obesity, ;15% to 35%
of total IL-6 is produced by adipose tissue, and IL-6 is a growth
factor in MM.27 Obesity can lead to elevated levels of bioavailable
insulin-like growth factor 1, which may increase MM cell proliferation
and inhibit apoptosis.28 Additionally, levels of adiponectin are lower
in obese individuals,29 and a recent study showed that higher levels
of adiponectin lowered the risk of MM30 as well as progression from
MGUS to MM.31
To date, only 2 studies on the association between obesity and
MGUS have been conducted. A study from the United States
based on 60 cases found a twofold increased risk of MGUS in
obese (BMI.30 kg/m2) vs nonobese women.32 Another screening
study from the United States, based on 365 cases of MGUS
identified through the National Health and Nutritional Examination
Survey, did not find an association.33 Both studies relied only on
BMI as a marker for obesity. However, obesity is an outcome of
many different factors, both physiological and behavioral, and could
therefore be a proxy for these factors that might independently have
an effect on MGUS risk. The association between obesity and
LC-MGUS has, to our knowledge, not been studied.
The aim of this study was to analyze the association between 11
different obesity assessment methods and MGUS and LC-MGUS
using data from a large population-based cohort, and, furthermore,
to analyze if obesity is a risk factor for progression from MGUS or
LC-MGUS to MM and other LP diseases.
Methods
Study population
This study is based on participants from the Age, Gene/
Environment Susceptibility–Reykjavik Study (AGES-RS), which is
a continuation of the population-based Reykjavik Study.34 The
Reykjavik Study began recruiting in 1967 a sample of more than
30 000 residents of Reykjavik born in 1907 to 1935. In 2002, the
AGES-RS started recruiting 5764 of the surviving members. A
detailed description of the study and data collection has been
published previously.34
All participants in the AGES-RS signed an informed consent form,
and the study was approved by the Icelandic National Bioethics
Committee (VSN-00-063-V35), the Icelandic Data Protection
Authority, and the Institutional Review Board of the National
Institute on Aging in the USA.
Material and measures
A 0.5-mL aliquot from the serum collected at AGES-RS study
baseline (2002-2006) was obtained for each study subject. Each
sample tube was labeled only with the participant’s coded ID
number and the specimen collection year. All specimens were
shipped on dry ice to the Multiple Myeloma Research Laboratory at
the National Cancer Institute, where protein assays were
performed. To identify MGUS cases in the AGES-RS cohort, we
performed conventional agarose-gel serum protein electrophoresis
(SPEP) for all subjects (Helena Laboratories, Beaumont, TX).
Samples with an equivocal or definite M-protein present on SPEP
were subjected to serum protein immunofixation for confirmation
and typing of the M-protein.11 Serum FLC assay (FREELITE; The
Binding Site Ltd., Birmingham, UK) was performed on all samples.35
All testing and interpretations were done by 2 individuals (R.C. and
D.B.) blinded to all demographics and other details pertaining to the
samples being tested. The results were merged with the data from
the original AGES-RS cohort.
MGUS cases were defined as having 1 or several M-protein bands
on SPEP and an M-protein concentration ,30 g/L.36 The criteria
for LC-MGUS were having no M-protein band visible on SPEP and
a pathological FLC ratio (,0.26 or .1.65) on FLC analysis in
combination with an increased concentration of the light chain
concerned (f-k .19.4 mg/L, f-l .26.3 mg/L).37
We included 11 different measures on obesity in our analysis.
Baseline measures were weight (kg), BMI (kg/m2), percent body fat
(%), fat (kg), total body fat (cm2), visceral fat (cm2), subcutaneous
fat (cm2), and 2 versions of abdominal circumference (cm). We also
included self-reported lifetime maximum weight and measured
midlife BMI (obtained from the Reykjavik Study data). Weight was
measured using a digital scale, and height was measured using a
stadiometer. Both measures were performed multiple times, and
mean numbers found. Percent body fat and fat were calculated from
bioelectric impedance (Xitron Hydra ECF/ICF Bio-Impedance
Spectrum Analyzer), a commonly used method for estimating body
composition. Computed tomography (CT) imaging of the abdomen
at the level of the L4/L5 vertebrae was performed to calculate total
body fat, visceral fat, subcutaneous fat, and abdominal circumfer-
ence.34 Abdominal circumference was also conventionally mea-
sured38 multiple times, and a mean number found. Midlife BMI was
calculated from weight and height measured at enrollment into the
Reykjavik Study. The mean age of participants at Reykjavik Study
entry was 53.3 years for women and 52.1 years for men.39
A total of 5764 persons were enrolled in AGES-RS. A total of
39 (0.7%) were excluded from analysis in this study, 21 subjects
because of previous LP diseases, 16 because of missing blood
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sample available for analysis, 1 subject had a missing consent form,
and 1 subject had an M-protein concentration above the limit for
MGUS and therefore fulfilling the criteria for smoldering MM. One
subject was excluded from the progression analysis only because of
zero follow-up days. Cases of MM and other LP diseases were found
by cross-linking the AGES-RS data with the Icelandic Cancer
Registry. The Icelandic Cancer Registry is in accordance with
internationally accepted standards as it has high diagnostic accuracy
and completeness (99%).40 End of follow-up was March 2014.
Statistical analysis
Logistic regression was used to estimate the association between
MGUS and LC-MGUS and the 11 obesity markers, and the results
are presented as odds ratios (ORs) with 95% confidence intervals
(95%CIs). Analyses were performed for both MGUS and LC-MGUS
separately and together. Adjustment was made for age and sex in a
multivariable analysis. Adjusting for height in multivariable models
where height is not taken into account in the measurement, such as
weight, waist circumference, and CT measures, did not affect the
estimates and was therefore not included in the analysis. To test
whether history of obesity had an effect on risk of MGUS/LC-MGUS,
individuals were grouped in accordance to their midlife BMI and BMI
at AGES-RS entry. Individuals with low midlife BMI and low BMI at
AGES-RS entry were the referent group for groups with an increase
in BMI, decrease in BMI, and constantly high BMI between these 2
time points. Cox proportional-hazard regression was used to test
whether obesity was a risk factor for progression to MM or other LP
diseases. Analyses were performed in R version 3.1.2.41
Results
A total of 5725 subjects were included in our analysis, with a mean
age of 77 years (range 66-98). In the sample, 3306 (58%)
individuals were women and 2419 were men. MGUS was identified
in 300 (5.2%) subjects and LC-MGUS in 275 (4.8%) subjects
(Table 1). Of the 300 MGUS patients, the Ig isotype was
immunoglobulin G (IgG) in 159 (53%) patients, IgA in 27 (9%),
IgM in 81 (27%), IgD in 1 (0.3%), and biclonal in 32 (10.7%). During
a median follow-up of 8 years, a total of 18 individuals progressed to
MM (17 of these from MGUS and 1 from LC-MGUS), and 11
individuals progressed to other LP diseases such as Hodgkin and
non-Hodgkin lymphoma, Waldenstro¨m’s macroglobulinemia, leuke-
mia, chronic lymphocytic leukemia, and acute lymphocytic leukemia
(2 of these from LC-MGUS).
No association was found between the 11 obesity markers and
MGUS or LC-MGUS (Table 2). Additionally, BMI history was not
Table 1. Characteristics of the study participants
Characteristics
Without MGUS, MGUS, LC-MGUS, MM, MM and other LP diseases,
n 5 5150 (93.9%) n 5 300 (5.2%) n 5 275 (4.8%) n 5 18 (3.1%)* n 5 29 (5.1%)*
Sex, n (%)
Female 3046 (59.1) 141 (47.0) 119 (43.3) 10 (55.6) 14 (48.3)
Male 2104 (40.9) 159 (53.0) 156 (56.7) 8 (44.4) 15 (51.7)
Mean age (range), y 76.8 (66-98) 78.3 (67-93) 79.4 (66-97) 77.8 (69-87) 77.4 (68-87)
BMI, mean (SD), kg/m2 27.0 (4.5) 26.7 (4.1) 27.0 (4.5) 27.1 (2.4) 26.5 (2.8)
BMI, % (n)
,25.0 1716 (34.0) 101 (34.1) 93 (34.2) 5 (27.8) 8 (27.6)
25.0-29.9 2222 (43.6) 146 (49.3) 121 (44.4) 10 (55.6) 18 (62.1)
$30.0 1154 (22.7) 49 (16.6) 58 (21.3) 3 (16.7) 3 (10.3)
BMI midlife, mean (SD), kg/m2 25.2 (3.6) 25.5 (3.7) 25.6 (3.8) 26.2 (2.7) 26.2 (3.2)
BMI midlife, n (%)
,25 2686 (52.4) 139 (46.7) 128 (46.7) 5 (27.8) 8 (27.6)
$25 2442 (47.6) 159 (53.3) 146 (53.3) 13 (72.2) 21 (72.4)
Weight, mean (SD), kg 75.3 (1.7) 75.4 (14.2) 76.4 (15.6) 77.2 (13.5) 76.8 (13.7)
Max weight, mean (SD), kg 80.7 (15.5) 82.4 (15.2) 83.1 (16.1) 85.4 (13.7) 85.7 (13.8)
Percent body fat (BIA), mean (SD), % 29.0 (7.9) 26.8 (8.4) 26.9 (7.7) 28.7 (7.6) 26.8 (7.9)
Fat (BIA), mean (SD), kg 22.0 (7.9) 20.5 (7.9) 20.7 (7.4) 22.7 (6.7) 20.6 (7.1)
Total body fat (CT), mean (SD), cm2 494.3 (167.0) 482.5 (166.5) 495.6 (173.7) 509.0 (130.0) 478.5 (151.5)
Visceral fat (CT), mean (SD), cm2 171.9 (79.5) 174.8 (85.1) 187.5 (86.9) 178.6 (91.4) 174.1 (92.4)
Subcutaneous fat (CT), mean (SD), cm2 257.3 (112.1) 241.0 (108.4) 238.6 (108.4) 261.1 (99.8) 237.1 (100.5)
Waist circumference (CT), mean (SD), cm 125.8 (14.0) 125.7 (13.4) 126.5 (14.2) 127.8 (11.8) 125.4 (13.3)
Waist circumference, mean (SD), cm 100.8 (12.1) 100.8 (11.2) 101.6 (11.5) 103.8 (9.2) 101.5 (9.9)
Missing values are 65 for BMI, 25 for midlife BMI, 57 for weight, 479 for maximum weight, 1666 for percent body fat and fat, 449 for the CT variables (total body fat, visceral fat,
subcutaneous fat, and CT waist circumference), and 53 for waist circumference.
BIA, bioelectrical impedance analysis; SD, standard deviation.
*Proportion of cases that progressed from MGUS or LC-MGUS.
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associated with MGUS and LC-MGUS when joint effects of midlife
BMI and BMI at study entry were examined, either when MGUS and
LC-MGUS were analyzed together (Table 3) or separately (data not
shown). Finally, based on a small number of cases, a nonsignificant
increased risk of progression (hazard ratio [HR], 2.64; 95% CI,
0.93-7.48) from MGUS/LC-MGUS to MM was found with high
midlife BMI (.25 kg/m2). When other LP cases were combined
with MM cases, the risk was statistically significantly increased (HR,
2.66; 95% CI, 1.17-6.05) (Table 4). There was no difference in
distribution of known risk factors for MGUS progression (isotype,
M-protein concentration, or FLC ratio) between individuals with low
(,25 kg/m2) and high ($25 kg/m2) BMI (data not shown).
Sensitivity analysis
Given the unusually high prevalence of LC-MGUS in our cohort (4.8%),
with a high prevalence of k cases (96%), we performed an additional
sensitivity analysis. As the distribution of log-transformed k and l values
resembled the normal distribution, we evaluated the effect of using the
97.5th percentile as a cutoff for normal values for the involved light-
chain. Using a definition of LC-MGUS as a pathological FLC ratio
of ,0.26 and .1.65, in combination with an increased concentration
of .40.0 mg/L of the light-chain involved, resulted in 52 LC-MGUS
cases (0.9%), of which 41 were k and 11 were l. Results from the
sensitivity analysis confirmed previous findings (data not shown).
Discussion
In this large population-based screening study on 5725 subjects,
we found that obesity is not associated with MGUS or LC-MGUS.
This was true independent of various obesity assessment tech-
niques, including BIA, CT scans, and other anthropometric
measurements such as height, weight, and waist circumference.
Additionally, we did not find history of obesity or weight change to
have an effect on MGUS/LC-MGUS. Interestingly, we found that
high BMI, measured at midlife, was associated with an increased
risk of progression to MM and other LP diseases.
We found no association between any of the 11 obesity measures
and MGUS or LC-MGUS. Previously, only 2 studies have examined
the association between MGUS and obesity, with conflicting
results.32,33 Our results are in line with the population-based National
Health and Nutritional Examination Survey study (N 5 12 482;
MGUS cases, 365) that found that BMI did not have an effect
on MGUS risk,33 whereas the Southern Community study
(N 5 1996; MGUS cases, 60) found a twofold increased risk
of MGUS in obese (BMI .30 kg/m2) vs nonobese women.32
Differences in the nature of the cohorts such as the cohort size, and
age, sex, and race distribution, as well as differences in recruitment of
participants, might explain the discrepancy between the studies. It
has been suggested that the increased risk of MM with increasing
BMI22,23 is explained by an increased risk of MGUS, which in turn
puts individuals at risk for developing MM.32 Our findings do not
confirm this. LC-MGUS is a newly defined disorder, and factors that
influence the development of the condition and its progression are
largely unknown. This is the first study to date to examine the
association with obesity.
Our results suggest that high BMI during midlife is associated with an
increased risk of progression from MGUS/LC-MGUS to MM and
other LP diseases later in life. This was not explained by known risk
factors for progression. Previous studies have indicated that obesity
might have a role in the etiology of MM.21,22,25,26 Recent pooled
analysis of 20 prospective studies found that waist circumference is a
risk factor for MM mortality and that BMI in early adulthood plays an
important role in myelomagenesis.25 Additionally, on the basis of the
available data, WHO recently concluded that there now is sufficient
evidence behind the association between body fatness and MM.6 To
date, only 1 study has examined the role of obesity in the progression
of MGUS to MM. A study on a cohort of US veterans within the
Veterans Health Administration system found an increased risk of MM
to be associated with both overweight (HR, 1.55; 95%CI, 1.16-2.06)
and obesity (HR, 1.98; 95% CI, 1.47-2.68) at MGUS diagnosis.42
We thus speculate that the observed risk of MM in individuals with
obesity is not because of increased risk of MGUS, but rather that they
have similar MGUS prevalence but a higher risk of progression.
Although our results are limited by the small number of cases and
should be interpreted with caution, the consistently high risk
Table 2. ORs and 95% CIs for association between obesity and
MGUS and LC-MGUS
MGUS LC-MGUS
n OR 95% CI n OR 95% CI
Baseline BMI
,25 101 Ref. Ref. 93 Ref. Ref.
25-29.9 146 1.14 0.88-1.49 121 1.07 0.81-1.41
$30 49 0.81 0.57-1.16 58 1.14 0.81-1.61
Midlife BMI
,25 139 Ref. Ref. 128 Ref. Ref.
$25 159 1.15 0.90-1.45 146 1.10 0.86-1.41
Weight 296 0.97 0.91-1.05 272 1.04 0.96-1.12
Max weight 266 1.03 0.96-1.11 240 1.02 0.94-1.10
Percent body fat (BIA) 192 0.95 0.80-1.13 174 1.15 0.96-1.39
Fat (BIA) 192 0.94 0.76-1.16 174 1.10 0.88-1.36
Total body fat (CT) 269 1.00 0.99-1.00 242 1.00 1.00-1.01
Visceral fat (CT) 269 1.00 0.98-1.01 242 1.01 1.00-1.02
Subcutaneous fat (CT) 269 1.00 0.99-1.01 242 1.00 0.99-1.01
Waist circumference (CT) 269 1.00 0.94-1.06 242 1.05 0.99-1.13
Waist circumference 296 0.97 0.89-1.07 272 1.02 0.93-1.12
Results were obtained with multinomial logistic regression. ORs for continuous variables
are per SD increase.
Ref., reference group.
Table 3. Joint effect of midlife BMI and baseline BMI on
MGUS/LC-MGUS
Joint BMI categories MGUS/LC-MGUS, n (%) OR 95% CI
Low midlife BMI, low current BMI 149 (27.8) Ref. Ref.
Low midlife BMI, medium current BMI 99 (21.0) 0.99 0.98-1.01
Low midlife BMI, high current BMI 16 (3.8) 1.00 0.97-1.04
High midlife BMI, low current BMI 45 (5.9) 1.03 1.00-1.04
High midlife BMI, medium current BMI 166 (22.6) 1.02 1.00-1.04
High midlife BMI, high current BMI 91 (19.0) 0.99 0.98-1.01
Results were obtained with logistic regression. Low midlife BMI, ,25 kg/m2; high midlife
BMI, $25 kg/m2; low current BMI, ,25 kg/m2; medium current BMI, 25-29.9 kg/m2; high
current BMI, $30 kg/m2.
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estimate both when MM was analyzed with and without other LP
diseases in our main analysis and sensitivity analysis, and a recent
study on the role of obesity in MGUS progression,42 strengthens the
notion that obesity plays a role in myelomagenesis and is possibly the
first identified modifiable risk factor for progression of MGUS to MM.
We did not find body weight or body composition at study baseline in
MGUS/LC-MGUS cases to be risk factors for progression to MM and
other LP diseases. The induction time for MM and other LP diseases is
long, and we do not have information on how long each individual has
met the criteria for MGUS/LC-MGUS before developing MM or other
LP diseases. A US-based screening study on a clinical cohort
concluded that when first clinically recognized, MGUS has likely been
present in an undetected state for a median duration of .10 years,43
and the interval from diagnosis of MGUS to diagnosis of MM or
related diseases ranges from 1 to 32 years (median, 10.4 years)
according to a follow-up study on 241 MGUS patients at Mayo
Clinic.44 Based on these results and the high mean age of the
population under study (77 years), it is possible that body weight and
composition at time of MGUS/LC-MGUS diagnosis is not a reliable
indicator for MM progression, as earlier life physique might be.
A major strength of this study is the design as this is a population-
based screened cohort study with high internal and external validity.
Another major strength is the use of various and precise measures to
assess obesity. BMI is a limited measure as it does not give
information on fat distribution and does not distinguish between lean
and fat mass; however, studies have shown that BMI is highly
correlated with other more precise measures of body composition
and fat distribution and has been shown to be at least approximately
equivalent in the ability to predict diseases.45 We found in our data
that the obesity measures were highly correlated (r5 0.37-0.95), but
the lack of an acceptable gold standard for measuring body fatness
makes it difficult to use only 1 measure. Using multiple markers for
late-life body fatness deals with the limitations that pertain to each
measure and strengthens our findings. An additional strength is the
consistency in the findings throughout the assessment methods.
Some limitations need to be kept in mind when interpreting the
results. Although this is a screened study, a selection bias might be
present. The mean age is high (77 years), and therefore, the cohort
might represent a selection of the population that is healthier than the
general population. Additionally, Iceland has an exclusively white
population, and in view of previous findings regarding MGUS
variance across ethnic groups,18,38 our results may not be applicable
to other races. As we do not have bone marrow samples from our
participants, we cannot therefore truly distinguish what could be
considered as smoldering MM. Missing data highly influence the
number of cases in our BIA models, mainly in our progression
analysis; these results should therefore be interpreted with caution.
A low number of cases that progressed could mean that we had
insufficient statistical power, which might affect our results.
In conclusion, in this Icelandic population-based cohort study,
obesity is not associated with MGUS or LC-MGUS. However,
based on 29 cases that progressed to MM or other LP diseases
later in life, our study found midlife obesity to be a risk factor for
progression among individuals diagnosed with MGUS/LC-MGUS.
This study provides evidence that obesity might be the first
modifiable risk factor for MGUS/LC-MGUS progression, but more
studies, both large-scale population-based studies and clinical
trials, are needed for better understanding of the etiology of MGUS/
LC-MGUS and MM.
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Table 4. HRs and 95% CIs for obesity and risk of progression from
MGUS to MM and other LP diseases
MM
MM and other LP
diseases
n HR 95% CI n HR 95% CI
Baseline BMI
,25.0 5 Ref. Ref. 8 Ref. Ref.
$25.0 13 1.33 0.47-3.75 21 1.30 0.57-2.94
Midlife BMI
,25.0 5 Ref. Ref. 8 Ref. Ref.
$25.0 13 2.64 0.93-7.48 21 2.66 1.17-6.05
Weight 18 1.10 0.84-1.44 29 1.04 0.84-1.29
Max weight 18 1.16 0.88-1.54 29 1.15 0.93-1.43
Percent body fat (BIA) 10 1.54 0.35-6.86 19 0.96 0.88-1.05
Fat (BIA) 10 1.92 0.81-4.57 19 0.79 0.29-2.13
Total body fat (CT) 17 1.00 0.98-1.02 28 1.00 0.98-1.01
Visceral fat (CT) 17 1.00 0.96-1.05 28 0.99 0.95-1.03
Subcutaneous fat (CT) 17 1.01 0.97-1.04 28 0.99 0.96-1.02
Waist circumference (CT) 17 1.01 0.97-1.04 28 0.96 0.79-1.16
Waist circumference 18 1.16 0.82-1.64 29 1.00 0.75-1.33
Results were obtained with Cox proportional hazard regression. HRs for continuous
variables are per SD increase.
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